EpiPen® 0.3mg Adrenaline Auto-Injector supply issues

EpiPen® 0.3mg Adrenaline Auto-Injector supply issues

May 3, 2018

Mylan has announced that due to manufacturing delays from their contract manufacturer, Meridian Medical Technologies, a Pfizer company, there are intermittent supply constraints on EpiPen® 0.3mg Adrenaline Auto-Injector in the UK.

To aid stock management, Alliance Healthcare (Mylan’s UK distributor for EpiPen®) will be supplying pharmacies on a prescription-only basis with a restriction of a maximum of two EpiPen® 0.3mg Auto-Injectors per prescription.
There are currently sufficient supplies of EpiPen Jr® 0.15mg Adrenaline Auto-Injectors in the UK.

Mylan say they are ‘working closely with Pfizer to manage supply carefully to avoid long-term supply shortages. Pfizer anticipates that production rates will increase over the coming months; however, at this time, cannot commit to a specific time for when the supply constraint will be fully resolved. We are confident in the safety and efficacy of the EpiPen® products being produced at Pfizer’s site and are working closely with them to alleviate the situation and achieve a steady state of supply as expeditiously as possible.

Patients with concerns over supply should visit their GP who may wish to prescribe an alternative brand if required, for example, Emerade® or Jext®.

Additional advice and information can be found on the Anaphylaxis campaign website here.

For more information please see attached statement from Mylan.


Posted in: ,

More Latest News >